Clinical Trial

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Study acronym: EmpowHER 208
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Protocol Amendment History 3 changes
notable Trial sites expanded: 30 -> 33 locations 2026-07-16
notable Trial sites expanded: 26 -> 30 locations 2026-07-03
notable Trial sites expanded: 21 -> 26 locations 2026-04-30
Trial Details
NCT Number NCT07102381
Lead Sponsor Jazz Pharmaceuticals
Collaborators: Jazz Pharmaceuticals Ireland Limited
Conditions HER2-positive Breast Cancer, Breast Cancer
Enrollment 125 participants
Start Date 2025-09-24
Primary Completion 2028-01-01 (estimated)
Study Completion 2030-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-15